Premium
The anticardiolipin antibody in elderly stroke patients: its effects on stroke types, recurrence, and the coagulation‐fibrinolysis system
Author(s) -
Tohgi H.,
Takahashi H.,
Kashiwaya M.,
Watanabe K.,
Hayama K.
Publication year - 1994
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1994.tb02685.x
Subject(s) - medicine , fibrinolysis , asymptomatic , stroke (engine) , incidence (geometry) , coagulation , gastroenterology , cardiology , surgery , mechanical engineering , physics , optics , engineering
Anticardiolipin antibody (aCL) is known as a risk marker for stroke, particularly in subjects younger than 50 years of age. We studied the effects of aCL on stroke types, recurrences, and the coagulation‐fibrinolysis system in 257 elderly patients (63.2 ± 11.4 years). Follow‐up was performed for 3.1 years on 184 patients, for whom the rate of symptomatic and asymptomatic reinfarcts on CT was studied. aCL was positive in 30 (12%) of the patients. The incidence of atherosclerotic changes in the cerebral arteries was not significantly different between aCL‐positive and aCL‐negative patients. The aCL‐positive patients had a greater rate of individuals not having any of the known risk factors (p<0.05), a greater incidence of cortical infarctions (p<0.05), more frequent symptomatic recurrences (p<0.05). They had significantly greater changes in molecular markers for the coagulation‐fibrinolysis system in the acute phase (p<0.05), but not in the chronic phase.